Insys Therapeutics $INSY anticipates Q3 revenue between $54mn and $55mn based on expected Subsys sales. On a mid-point basis of $54.5mn, revenue will be down by more than 40%, y-o-y. The company expects positive cash flows at this level, which in turn help to meet its product development and growth objective.